Quit Smoking Success Rates by Method

Quitting smoking has a measurement problem. Ask ten studies what the “success rate” of any given method is, and you’ll get ten different answers — because they’re measuring different things. How long does someone need to stay quit to count? Is “not a single puff” the standard, or does “significantly reduced smoking” qualify? Are we looking at 4 weeks, 6 months, or 12 months?

These aren’t pedantic questions. They’re the reason why the numbers you see cited for different quit methods vary so wildly. A method that claims “60% success” at 4 weeks may show only 15% success at 12 months. Both numbers are technically correct. Neither is dishonest. But only one of them is useful if your goal is to actually quit for good.

In this article, we’re going to cut through the noise. Every number cited here specifies the timeframe and the standard used. The primary sources are Cochrane systematic reviews — the gold standard of medical evidence synthesis — along with major randomized controlled trials published in peer-reviewed journals.

Before the Numbers: Understanding “Success”

The Measurement Problem

Clinical trials typically define success as continuous abstinence (not a single puff) or point prevalence abstinence (not smoking at the time of measurement, regardless of any lapses in between). These give different numbers:

• Continuous abstinence is the strictest measure and produces the lowest success rates
• Point prevalence is more generous and produces higher rates
• Biochemically verified (confirming abstinence with a cotinine or carbon monoxide test) produces lower rates than self-reported abstinence

For consistency, we’ll focus primarily on biochemically verified continuous abstinence at 6-12 months, which is the most meaningful measure for long-term quitting.

The Denominator Problem

Success rates also depend on who’s being counted. Rates from clinical trials (motivated volunteers who signed up for a study) are typically higher than real-world rates (everyone who tries to quit, including half-hearted attempts). Where possible, we’ll note this distinction.

The Bottom Line: When comparing methods, always check: What timeframe? What definition of “quit”? Verified or self-reported? Clinical trial or real-world? The method comparisons below standardize these variables as much as the data allows.

Quit smoking success rates by method (6-12 month abstinence) — Sources: Cochrane Database of Systematic Reviews; EAGLES Trial, The Lancet, 2016

Method 1: Cold Turkey (Unassisted)

The Data

Cold turkey — quitting abruptly without any medications, nicotine replacement, or formal support — is the most common quit method. Approximately 60-70% of quit attempts are made this way, according to CDC survey data.

The success rates are sobering:

• At 4 weeks: Approximately 15-25% are still abstinent
• At 6 months: Approximately 5-7%
• At 12 months: Approximately 3-5% (biochemically verified continuous abstinence)

A large meta-analysis by Hughes et al. (2004) in Addiction pooled data from multiple studies and estimated the unassisted long-term quit rate at approximately 3-5%.

Why It’s So Low

This isn’t because people who try cold turkey lack willpower. It’s because they’re facing the full neurochemical onslaught of nicotine withdrawal — receptor upregulation, dopamine deficit, and the complete catalog of withdrawal symptoms — with no pharmacological buffer. They’re also typically not receiving behavioral support for managing triggers and habit loops.

The Important Nuance

Despite the low per-attempt success rate, cold turkey has produced the largest total number of successful ex-smokers, simply because so many people try it. If you try cold turkey 20 times, your cumulative probability of eventual success is considerably higher than 3-5%. Most long-term ex-smokers in population surveys report having quit cold turkey — but many of them tried multiple times before it stuck.

Method 2: Nicotine Replacement Therapy (NRT) — Single Product

NRT products include patches, gum, lozenges, inhalers, and nasal spray. They deliver controlled doses of nicotine without the combustion products, MAO inhibitors, and other harmful chemicals in cigarette smoke.

The Data

The Cochrane Review of NRT (Hartmann-Boyce et al., 2018), which analyzed 136 trials involving over 64,000 participants, found:

• Any single NRT product vs. placebo: Increases quit rates by 50-60% relative to placebo
• Absolute quit rates at 6+ months: Approximately 15-20% (vs. ~10% for placebo in clinical trial settings)
• Number Needed to Treat (NNT): Approximately 14 — meaning you need to treat 14 people with NRT to produce 1 additional quitter beyond what placebo would achieve

By Product Type

NRT Product	Relative Risk vs. Placebo	Notes
Patch (16hr or 24hr)	1.51	Steady delivery; easiest to use; no behavioral replacement
Gum (2mg or 4mg)	1.49	Oral replacement; can dose on demand; 4mg more effective for heavy smokers
Lozenge	1.52	Similar to gum; dissolves without chewing
Inhaler	1.90	Mimics hand-to-mouth ritual; prescription in most countries
Nasal Spray	2.02	Fastest NRT delivery (but still much slower than cigarettes); highest user-reported satisfaction

Why NRT Works But Isn’t Magic

NRT reduces withdrawal severity by maintaining partial nicotinic receptor activation. It doesn’t eliminate cravings, but it takes the sharp edge off, making the first weeks more manageable. However, it doesn’t address the behavioral component of addiction — the habit loops, the triggers, the rituals. This is why NRT alone has modest effects and why combining it with behavioral support significantly improves outcomes.

Method 3: Combination NRT

The Data

Using two NRT products simultaneously — typically a patch (for sustained baseline nicotine) plus a short-acting product like gum, lozenge, or inhaler (for acute craving management) — produces meaningfully better results than any single NRT product.

The Cochrane Review found:

• Combination NRT vs. single NRT: Approximately 15-36% higher quit rates with combination use
• Absolute quit rates at 6+ months: Approximately 20-25%
• This combination is recommended as first-line therapy by most clinical guidelines

Why Combination Works Better

The patch provides a steady nicotine baseline, preventing the worst withdrawal symptoms. The short-acting product gives you a tool for acute cravings — the moments when you’d normally reach for a cigarette. Together, they address both the tonic (constant) and phasic (acute) components of nicotine dependence.

The Bottom Line: If you’re going to use NRT, use two products. The patch alone is good. Patch plus gum/lozenge is meaningfully better. This is one of the most well-supported findings in cessation medicine.

Method 4: Varenicline (Champix/Chantix)

Varenicline is a prescription medication that works directly at the nicotinic receptor level. It’s a partial agonist at the α4β2 nAChR — meaning it partially activates the receptor (enough to reduce withdrawal and cravings) while simultaneously blocking nicotine from fully activating it (reducing the reward if you do smoke).

The Data

Varenicline is the most effective single-agent pharmacotherapy for smoking cessation:

• Cochrane Review (Cahill et al., 2016): Varenicline vs. placebo showed a relative risk of 2.24 — more than doubling quit rates
• Absolute quit rates at 6+ months: Approximately 25-33% (vs. ~10-12% for placebo)
• NNT: Approximately 8 — meaning 1 in 8 people treated with varenicline will quit who wouldn’t have otherwise
• Head-to-head vs. NRT: The EAGLES trial (Anthenelli et al., 2016, The Lancet), the largest cessation trial ever conducted with over 8,000 participants, found varenicline superior to nicotine patch (quit rates: 25.5% vs. 21.8% at 24 weeks)

Safety Profile

Varenicline’s safety has been extensively studied. Early post-marketing reports raised concerns about psychiatric side effects (depression, suicidal ideation). The EAGLES trial was specifically designed to address this:

• No significant increase in neuropsychiatric adverse events vs. placebo, including in participants with psychiatric histories
• The FDA removed its “black box” warning for varenicline in 2016 based on this and other data
• Most common side effects: Nausea (25-30%, usually mild and transient), insomnia, abnormal dreams
• In 2021, Pfizer voluntarily recalled Chantix due to nitrosamine contamination above acceptable levels — a manufacturing issue, not a drug safety issue. Generic versions remain available in many countries.

Method 5: Bupropion (Wellbutrin/Zyban)

Bupropion is an atypical antidepressant that inhibits the reuptake of dopamine and norepinephrine. It was originally developed for depression and discovered to reduce smoking urges as a side effect.

The Data

• Cochrane Review (Howes et al., 2020): Bupropion vs. placebo showed a relative risk of 1.64 for sustained abstinence
• Absolute quit rates at 6+ months: Approximately 15-20%
• NNT: Approximately 11
• Head-to-head vs. varenicline: The EAGLES trial found bupropion inferior to varenicline but superior to placebo (quit rate: 22.6% at 24 weeks)

How It Works

Bupropion addresses the dopamine deficit component of nicotine withdrawal. By blocking dopamine reuptake, it partially compensates for the reduced dopamine signaling that occurs when nicotine is removed. It also has mild antagonist effects at nicotinic receptors.

Who It May Suit

• People who want to avoid nicotine-containing products entirely
• Smokers with co-occurring depression (though it should be prescribed by a physician who can monitor appropriately)
• Those who experienced side effects with varenicline
• Can be combined with NRT for enhanced effects

Method 6: Behavioral Counseling (Alone)

The Data

Professional behavioral counseling — individual, group, or telephone-based — helps people identify triggers, develop coping strategies, and build motivation. As a standalone treatment:

• Cochrane Review (Lancaster & Stead, 2017): Individual counseling vs. minimal contact showed a relative risk of 1.57
• Absolute quit rates at 6+ months: Approximately 7-13% depending on intensity and duration
• More intensive counseling (multiple sessions, longer duration) produces better results than brief interventions
• Telephone quitlines (such as 1-800-QUIT-NOW in the US) have been shown to increase quit rates by 25-50% relative to self-help alone

Types of Behavioral Support

Type	Description	Evidence Level
Individual counseling	1-on-1 with a trained cessation specialist	Strong
Group therapy	Structured group sessions, often 6-8 weeks	Strong
Telephone quitlines	Proactive callbacks from trained counselors	Strong
Text-based programs	Scheduled text messages with tips and encouragement	Moderate
Mobile apps	Self-guided programs with tracking and tips	Limited but growing
Online communities	Peer support through forums and social media	Limited formal evidence; strong anecdotal support

Why Counseling Works

Counseling addresses the behavioral and psychological components of addiction that medication cannot reach. It helps with:

• Identifying personal triggers and developing specific strategies for each
• Building a quit plan with concrete steps
• Developing coping skills for stress and negative emotions
• Accountability and ongoing support
• Relapse prevention planning

Method 7: Combination Therapy (Medication + Counseling)

This is the gold standard. Every major clinical guideline — from the US Public Health Service to the UK’s NICE — recommends combining pharmacotherapy with behavioral support.

The Data

• US Clinical Practice Guideline (Fiore et al., 2008): Combination of medication + counseling showed the highest quit rates across all reviewed studies
• Absolute quit rates at 6+ months: Approximately 25-35%
• Compared to either alone: Combination therapy is approximately 40-60% more effective than medication alone, and 2-3x more effective than counseling alone
• NNT: Approximately 5-7 — the best of any approach

Why Combination Dominates

This makes intuitive sense once you understand the dual nature of smoking addiction:

• Medication handles the neurochemical component — withdrawal symptoms, receptor management, dopamine regulation
• Counseling handles the behavioral component — habit loops, triggers, coping strategies, motivation maintenance

Neither alone addresses the full problem. Together, they cover both fronts.

The Cochrane Review by Stead et al. (2016) on combined pharmacotherapy and behavioral interventions concluded that the combination provides a clear, clinically significant benefit over either approach alone.

The Bottom Line: If you’re serious about maximizing your odds, combination therapy (medication + counseling) is what the evidence supports. The success rates are 5-10x higher than unassisted cold turkey. This isn’t opinion — it’s the consistent finding across hundreds of clinical trials.

Head-to-Head Comparison: The Summary Table

Method	6-12 Month Quit Rate	Relative Effectiveness	NNT
Cold turkey (unassisted)	3-5%	Baseline	N/A
Single NRT (patch, gum, etc.)	15-20%	3-4x cold turkey	~14
Combination NRT (patch + short-acting)	20-25%	5-6x cold turkey	~10
Bupropion	15-20%	3-4x cold turkey	~11
Varenicline	25-33%	6-8x cold turkey	~8
Behavioral counseling alone	7-13%	2-3x cold turkey	~15
Medication + counseling	25-35%	6-10x cold turkey	~5-7

Note: These are approximate ranges based on multiple Cochrane reviews and major clinical trials. Actual rates vary by study, population, and measurement criteria.

The Number Needed to Treat: What It Means In Practice

The “Number Needed to Treat” (NNT) is one of the most useful statistics in medicine. It tells you how many people need to receive a treatment for one additional person to benefit compared to the control group.

• NNT of 8 (varenicline) means: for every 8 people who take varenicline, 1 additional person will quit who wouldn’t have quit with placebo. The other 7 aren’t harmed — they just didn’t get the additional benefit.
• NNT of 5-7 (combination therapy) means: for every 5-7 people who receive combined medication and counseling, 1 additional person quits.

For context, many widely accepted medical treatments have NNTs of 20-100. An NNT of 5-7 is remarkably effective by medical standards.

Why “Success Rates” Vary So Wildly in Popular Media

If you’ve searched online for quit rates and found wildly contradictory numbers, here’s why:

Study Design Differences

• Clinical trials involve motivated, screened participants with exclusion criteria — rates are higher
• Real-world studies include all comers — rates are lower
• Self-help books and commercial programs often cite their best numbers without context

Timeframe Differences

• 4-week quit rates look impressive but don’t predict long-term success
• 6-month rates are more meaningful
• 12-month rates are the gold standard but are reported less often (they’re lower and less marketable)

Verification Differences

• Self-reported abstinence rates are typically 15-25% higher than biochemically verified rates
• Many popular sources cite self-reported numbers

Population Differences

• Success rates differ by age, smoking history, nicotine dependence level, mental health status, and socioeconomic factors
• A method that works well for light social smokers may be less effective for heavy, long-term smokers

What the Data Says About Relapse

Understanding relapse patterns is crucial because quitting isn’t a single event — it’s a process that often involves setbacks.

• Most relapses occur within the first 3 months. A study by Hughes et al. (2004) found that approximately 60-70% of relapses happen in the first month.
• After 12 months of abstinence, relapse rates drop to approximately 2-5% per year.
• After 5 years, relapse is very rare — less than 1% per year.
• The leading triggers for relapse are alcohol use, stress, weight gain concerns, and social situations involving smoking.

The data also shows that a lapse (one cigarette) doesn’t have to become a relapse (return to smoking). Studies by Shiffman et al. (2006) in Journal of Consulting and Clinical Psychology found that approximately 50% of people who have a single lapse do not go on to relapse fully — especially if they have a plan for how to respond to a slip.

Practical Recommendations Based on the Evidence

For the Best Odds

1. Talk to a healthcare provider about medication options (varenicline, combination NRT, or bupropion)
2. Pair medication with behavioral support — call a quitline (1-800-QUIT-NOW in the US), join a cessation group, or see a counselor trained in cessation
3. Set a quit date 1-2 weeks in advance and begin medication before that date (varenicline is typically started 1 week before the quit date; the patch can be started on the quit date)

If You Prefer Not to Use Medication

1. Use a quitline or counseling — it still roughly doubles your odds vs. going completely alone
2. Create a detailed trigger plan — list your top 10 smoking triggers and write a specific alternative behavior for each
3. Enlist social support — having a quit buddy or telling friends and family improves outcomes

If You’ve Tried and Failed Before

1. Try a different method — if cold turkey didn’t work, try medication. If a patch didn’t work, try varenicline. Each method works through different mechanisms.
2. Don’t count previous attempts as failures — they’re learning opportunities. Each attempt increases your chance of future success.
3. Consider combination therapy — if you’ve been trying one thing at a time, combining approaches may provide the edge you need.

The evidence is clear: effective treatments exist, they dramatically improve your odds, and combining approaches works best. The playing field isn’t level when you bring the right tools.

Sources and Further Reading

• Hartmann-Boyce, J., et al. (2018). “Nicotine replacement therapy versus control for smoking cessation.” Cochrane Database of Systematic Reviews, 5, CD000146.
• Cahill, K., et al. (2016). “Nicotine receptor partial agonists for smoking cessation.” Cochrane Database of Systematic Reviews, 5, CD006103.
• Howes, S., et al. (2020). “Antidepressants for smoking cessation.” Cochrane Database of Systematic Reviews, 4, CD000031.
• Stead, L.F., et al. (2016). “Combined pharmacotherapy and behavioural interventions for smoking cessation.” Cochrane Database of Systematic Reviews, 3, CD008286.
• Lancaster, T., & Stead, L.F. (2017). “Individual behavioural counselling for smoking cessation.” Cochrane Database of Systematic Reviews, 3, CD001292.
• Anthenelli, R.M., et al. (2016). “Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch (EAGLES).” The Lancet, 387(10037), 2507-2520.
• Hughes, J.R., et al. (2004). “Natural history of attempts to stop smoking.” Nicotine & Tobacco Research, 6(4), 617-626.
• Shiffman, S., et al. (2006). “Analyses of lapses and relapses.” Journal of Consulting and Clinical Psychology, 74(4), 761-770.
• Fiore, M.C., et al. (2008). Treating Tobacco Use and Dependence: 2008 Update. US Department of Health and Human Services.
• Centers for Disease Control and Prevention. “Quitting Smoking Among Adults — United States, 2000-2015.”